Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia.

Haematologica - 1 Aug 2025

Medina-Gil Daniel, Palomo Laura, Navarro Víctor, Lázaro Gonzalo, Martín-Mur Beatriz, Hernández Cristina, Castells Oriol, Sánchez Belén, Muñoz-Torres Pau Marc, Pagès Carlota, Pujadas Gemma, Esteve-Codina Anna, Cabirta Alba, Ferrà Christelle, Alcoceba Miguel, Terol Maria José, Andreu Rafael, Martí Mercè, Abrisqueta Pau, Bosch Francesc, Crespo Marta

Abstract excerpt

Continuous treatment with ibrutinib not only exerts tumor control but also enhances T-cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib...

Read the complete abstract on PubMed

Topics

Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Agammaglobulinaemia Tyrosine Kinase
Tumor Microenvironment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Piperidines

Adenine

Protein Kinase Inhibitors

Female

Male

Pyrazoles

Aged

Middle Aged

Mutation

Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 40079085
DOI: 10.3324/haematol.2024.286663
PMCID: PMC12358782

Genes

BTK
TMBIM6
CXCL12
CXCR4
MYC

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia.PMID 40079085Read ↗

Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.Semantic proximity Read ↗

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapseSemantic proximity Read ↗

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity Read ↗

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Semantic proximity Read ↗

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasSemantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLLSemantic proximity Read ↗

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read ↗

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemiaSemantic proximity Read ↗

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read ↗

Ibrutinib treatment of CLL: the cancer fights back.Semantic proximity Read ↗

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.